Miruvor
Sign up
The short answer

What studies of LOLA (L-ornithine L-aspartate) found

1paper on LOLA (L-ornithine L-aspartate)
30people in 1 study testing LOLA (L-ornithine L-aspartate) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for cognition (brain fog).

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: LOLA (L-ornithine L-aspartate) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. LOLA (L-ornithine L-aspartate) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Cognition (brain fog)1 study · 30 people took LOLA (L-ornithine L-aspartate) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (30 in all); not all results were tested against chance.

Studies with no comparison group30 in the study

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of LOLA (L-ornithine L-aspartate) on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (30 in all)
  • Not all results were tested against chance
See the 1 study
  1. [Mild post-COVID syndrome in young patients]. (2023)

    People in the study
    30 in the study
    Dose
    —
    Outcome
    testing results for changes in cognitive functions
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. [Mild post-COVID syndrome in young patients].2023 · no comparison group · 30 in the study
    Summary

    This single-arm study enrolled 30 students aged 18 to 24 who had COVID-19 and reported decreased attention, memory impairment, and other cognitive disorders. The setting was post-COVID syndrome, and the abstract describes patients without pronounced impairment of intelligence, memory, speech, and learning ability. All patients were treated with L-ornithine-L-aspartate; the abstract does not report dose, route, schedule, or treatment duration. There was no comparison group, and the abstract does not report randomisation, blinding, or a follow-up period. The recorded outcomes were objective findings and testing results for changes in cognitive functions. The abstract reports an improvement in objective findings and an improvement in testing results for changes in cognitive functions. The study size recorded is 30 enrolled; the abstract does not give a separate number started or analysed. Harms, side effects, and withdrawals are not reported. The authors' conclusion states that improvement in objective findings and cognitive testing was reported. The abstract does not state limitations.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime